This is a China news story, published by Yahoo Finance, that relates primarily to Novo Nordisk's news.
For more China news, you can click here:
more China newsFor more Novo Nordisk's news, you can click here:
more Novo Nordisk's newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Yahoo Finance, you can click here:
more news from Yahoo FinanceOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
Raffles Hospital Beijing. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest huge Chinese market news, Novo news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
obesity treatmentsReuters
•80% Informative
Novo Nordisk's hugely popular weight-loss drug Wegovy has been approved in China .
China is estimated to hold the highest number of overweight or obese people.
Number of overweight adults in China projected to reach 540 million by 2030 , 2.8 times higher than 2000 levels.
Novo said in March it would initially target Chinese patients willing to pay out-of-pocket for the weekly injection.
VR Score
91
Informative language
98
Neutral language
67
Article tone
formal
Language
English
Language complexity
52
Offensive language
possibly offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links